TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy

Ahronian LG, Sahu S, Zhang M, Patel AS, Geng K, Bhattacharya R, Falchook GS, Goldman JW, Spira AI, Punekar SR, Spigel DR, Wang JS, Skoulidis F, Stephens J, Meynardie M, Powell JM, Lopez A, Ranieri M, Ploszaj MA, Tan YJ, Lee YT, Yu Y, Deng J, Chen T, McCarren P, Tsai A, Hussain SS, Doyon B, Amemiya K, Ermolieff J, Shahagadkar P, Das NM, Flynn LR, Shields JA, Danielczyk L, McMillan BJ, Mignault A, Meier SR, Wu HJ, Guerin DJ, Whittington DA, Min C, Sienczylo I, Maxwell JP, DiBenedetto HJ, Watanabe H, Haines BB, Huang A, Crystal A, Andersen JN, Wu X, Wong KK. TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy. Cancer Res. 2025 Aug 29. doi: 10.1158/0008-5472.CAN-25-0998. Epub ahead of print. PMID: 40882030.


Related Posts